Alvotech
(ALVOW)
undefined
undefined%
At close: undefined
2.75
0.00%
After-hours Dec 13, 2024, 03:49 PM EST
Company Description
Alvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets.
The company is based in Iceland.
Alvotech
| Country | IS |
| IPO Date | Jun 16, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 999 |
| CEO | Robert Wessman |
Contact Details
Address: Saemundargata 15-19 Reykjavik, IS | |
| Website | https://www.alvotech.com |
Stock Details
| Ticker Symbol | ALVOW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001898416 |
| CUSIP Number | L01800116 |
| ISIN Number | LU2458333858 |
| Employer ID | 98-1629342 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert Wessman | Chief Executive Officer, Founder & Executive Chairman |
| Faysal Kalmoua | Chief Operating Officer & Director |
| Joel Morales | Chief Financial Officer |
| Anil Okay | Chief Commercial Officer |
| Christina Siniscalchi | Chief Quality Officer |
| Giedrius Zunda | Chief Technical Officer |
| Jenny Sif Steingrimsdottir | Vice President of People & Culture |
| Joseph E. McClellan | Chief Scientific Officer |
| Ming Li | Chief Strategy Officer |
| Tanya Zharov | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 6-K | Filing |
| Nov 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 04, 2024 | 6-K | Filing |
| Oct 22, 2024 | 6-K | Filing |
| Oct 10, 2024 | 6-K | Filing |
| Aug 29, 2024 | 424B3 | Filing |
| Aug 21, 2024 | F-3 | Filing |
| Aug 15, 2024 | 6-K | Filing |
| Aug 15, 2024 | 6-K | Filing |
| Jul 22, 2024 | 6-K | Filing |